Last reviewed · How we verify
teriparatide and raloxifene
This combination therapy stimulates bone formation through PTH receptor activation while simultaneously blocking estrogen receptor-mediated bone resorption.
This combination therapy stimulates bone formation through PTH receptor activation while simultaneously blocking estrogen receptor-mediated bone resorption. Used for Osteoporosis in postmenopausal women.
At a glance
| Generic name | teriparatide and raloxifene |
|---|---|
| Also known as | Forteo, Evista |
| Sponsor | Medical University of Vienna |
| Drug class | Combination therapy: PTH analog and selective estrogen receptor modulator (SERM) |
| Target | PTH1 receptor (teriparatide); estrogen receptor alpha and beta (raloxifene) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Bone Metabolism |
| Phase | FDA-approved |
Mechanism of action
Teriparatide is a recombinant parathyroid hormone analog that activates PTH1 receptors on osteoblasts to promote bone formation and increase bone mineral density. Raloxifene is a selective estrogen receptor modulator (SERM) that acts as an estrogen agonist in bone tissue to inhibit osteoclast-mediated bone resorption. Together, they provide complementary anabolic and anti-resorptive effects for enhanced bone strengthening.
Approved indications
- Osteoporosis in postmenopausal women
Common side effects
- Nausea
- Dizziness
- Leg cramps
- Hot flushes
- Venous thromboembolism risk (raloxifene component)
Key clinical trials
- Post-fracture Medication and Mortality
- Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window? (PHASE4)
- Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis (PHASE4)
- Back Pain in Patients With Severe Osteoporosis
- 2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis (PHASE4)
- Effects of Teriparatide in Postmenopausal Women With Osteoporosis (PHASE4)
- Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis (PHASE4)
- Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- teriparatide and raloxifene CI brief — competitive landscape report
- teriparatide and raloxifene updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI